MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

How Pfizer ended up passing on my GLP-1 work back in the early ’90s

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class of drugs. But the

September 9, 2024

Ascentage’s olverembatinib gains approval in Macau for leukaemia

Ascentage Pharma’s olverembatinib is indicated for the treatment of haematological malignancy indications. Credit: Nemes Laszlo / Shutterstock. Ascentage Pharma has obtained approval for its new

July 8, 2024

Resilience cuts 120 employees at a former bluebird gene therapy site

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 9, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.